This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Deeken, J. F. Articles by Löscher, W. Search for Related Content PubMed PubMed Citation Articles by Deeken, J. F. Articles by Löscher, W. Related Collections Cellular Pathobiology: Metabolism and Physiology Therapeutics and Targets Therapeutics and Targets: Drug Mechanisms and Resistance

The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses

Authors' Affiliations: ¹ Lombardi Cancer Center, Georgetown University Medical Center, Washington, D.C. and ² Department of Pharmacology, Toxicology and Pharmacology, University of Veterinary Medicine, Hannover, Germany

Requests for reprints: John F. Deeken, Lombardi Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road, NW, Washington, D.C. 20007. Phone: 202-444-3958; E-mail: deekenj{at}georgetown.edu.

Abstract

Despite scientific advances in understanding the causes and treatment of human malignancy, a persistent challenge facing basic and clinical investigators is how to adequately treat primary and metastatic brain tumors. The blood-brain barrier is a physiologic obstruction to the delivery of systemic chemotherapy to the brain parenchyma and central nervous system (CNS). A number of physiologic properties make the endothelium in the CNS distinct from the vasculature found in the periphery. Recent evidence has shown that a critical aspect of this barrier is composed of xenobiotic transporters which extrude substrates from the brain into the cerebrospinal fluid and systemic circulation. These transporters also extrude drugs and toxins if they gain entry into the cytoplasm of brain endothelial cells before they enter the brain. This review highlights the properties of the blood-brain barrier, including the location, function, and relative importance of the drug transporters that maintain this barrier. Primary and metastatic brain malignancy can compromise this barrier, allowing some access of chemotherapy treatment to reach the tumor. The responsiveness of brain tumors to systemic treatment found in past clinical research is discussed, as are possible explanations as to why CNS tumors are nonetheless able to evade therapy. Finally, strategies to overcome this barrier and better deliver chemotherapy into CNS tumors are presented.

This article has been cited by other articles:

				R. W. Robey, A. Lazarowski, and S. E. Bates P-Glycoprotein--a Clinical Target in Drug-Refractory Epilepsy? Mol. Pharmacol., May 1, 2008; 73(5): 1343 - 1346. [Abstract] [Full Text] [PDF]

				M. D. Groves Leptomeningeal Metastases: Still a Challenge ASCO Educational Book, January 1, 2008; 2008(1): 80 - 87. [Abstract] [Full Text] [PDF]

				N. A. de Vries, J. Zhao, E. Kroon, T. Buckle, J. H. Beijnen, and O. van Tellingen P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan Clin. Cancer Res., November 1, 2007; 13(21): 6440 - 6449. [Abstract] [Full Text] [PDF]

				G. C. Prendergast AACR Cancer Reviews Online: A new resource for cancer researchers Cancer Reviews Online Content, April 1, 2007; 2007(1): 1 - 2. [Full Text] [PDF]

				J. B. Aragon-Ching and J. A. Zujewski CNS Metastasis: An Old Problem in a New Guise Clin. Cancer Res., March 15, 2007; 13(6): 1644 - 1647. [Abstract] [Full Text] [PDF]

				N. U. Lin and E. P. Winer Brain Metastases: The HER2 Paradigm Clin. Cancer Res., March 15, 2007; 13(6): 1648 - 1655. [Abstract] [Full Text] [PDF]